A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

@article{Temkin2010API,
  title={A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.},
  author={Sarah M Temkin and Seiko Diane Yamada and Gini F. Fleming},
  journal={Gynecologic oncology},
  year={2010},
  volume={117 3},
  pages={473-6}
}
OBJECTIVE The mTOR inhibitor, temsirolimus, has clinical activity in the treatment of gynecologic malignancies, particularly endometrial cancer. We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus. METHODS Women with a history of advanced or recurrent gynecologic malignancy refractory to curative therapy were enrolled. A starting dose of 1mg/m(2) of intravenous topotecan days 1, 8 and 15 was combined with 25mg temsirolimus days 1, 8, 15 and… CONTINUE READING
34 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

A phase II study of oral mammalian target of rapamycin ( mTOR ) inhibitor , RAD 001 ( everolimus ) , in patients with recurrent endometrial carcinoma ( EC )

  • BM Slomovitz, KH Lu, T Johnston, M Munsell, LM Ramondetta, RR Broaddus
  • J Clin Oncol ( Meeting Abstracts )
  • 2008

A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma

  • BM Slomovitz, KH Lu, T Johnston, M Munsell, LM Ramondetta, RR Broaddus
  • (EC). J Clin Oncol (Meeting Abstracts)
  • 2008

A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b

  • AM Oza, L Elit, D Provencher, JJ Biagi, L Panasci, J Sederias
  • J Clin Oncol (Meeting Abstracts)
  • 2008

A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer

  • N Colombo, S McMeekin, P Schwartz, J Kostka, C Sessa, P Gehrig
  • J Clin Oncol (Meeting Abstracts)
  • 2007

Novel biologic therapies for the treatment of endometrial cancer

  • J Wolf, BM Slomovitz
  • Int J Gynecol Cancer 2005;15:411
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…